FEB 21, 2017 11:44 AM PST

TSRI-Invented Compound Ozanimod Shows Positive Results in Late-Stage Clinical Trial for Relapsing Multiple Sclerosis

Image Credit: Pixabay

February 21, 2017 – Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple sclerosis relapse.

Relapsing multiple sclerosis is a form of the disease where patients experience a periodic worsening of symptoms. Sensory and motor loss of function leads to increased disability, and patients can need a cane or wheelchair. A signature of the disease is the appearance of lesions in the brain, which are linked to inflammation and can show up through MRI detection during active periods of multiple sclerosis relapse.

Ozanimod, discovered by TSRI Professors Hugh Rosen and Ed Roberts and their laboratories, acts as a sphingosine 1-phosphate 1 (S1PR1) receptor agonist—modulating S1PR1 signaling and blocking sources of inflammation. Rosen and Roberts went on to co-found Receptos, a clinical stage biopharmaceutical company that took ozanimod into Phase 1, 2 and 3 clinical trials and was then acquired by Celgene. Ozanimod is the first New Chemical Entity discovered from a starting point in the NIH Common Fund Molecular Libraries Initiative to reach and succeed in advanced clinical studies.

As reported by Celgene, results from the randomized, Phase 3, double-blind, double-dummy, active-controlled SUNBEAM study among 1,346 participants show that ozanimod met its primary endpoint in reducing annualized relapse rate (ARR) of relapsing multiple sclerosis, compared with an alternate drug treatment called weekly interferon (IFN) β-1a (Avonex®).

Administered at doses of both 1 mg and 0.5 mg, ozanimod demonstrated statistically significant and clinically meaningful improvements, compared to Avonex®, for the primary endpoint of ARR and the measured secondary endpoints of the number of MRI-detected lesions and the number of new or enlarging “T2” MRI lesions at after a year of treatment.

“It is exciting and rewarding to see the results of this new Phase 3 trial, which confirm the safety profile from the two-year extension data from the Phase 2 RADIANCE study and underscore ozanimod’s efficacy in reducing the burden of MS symptoms on patients and their families,” said Rosen. “We look forward to seeing the full study results, as well as the results from the Phase 3 study evaluating ozanimod in patients with ulcerative colitis.”

Scientists involved in the trial plan to present the full Phase 3 trial results at an upcoming international scientific meeting.

This article was originally published on Scripps.edu.

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
MAR 23, 2021
Cell & Molecular Biology
One Metabolic Problem May Cause Multiple Diseases
MAR 23, 2021
One Metabolic Problem May Cause Multiple Diseases
Patients with a disease often see specialists, and there may not be much communication among them when individuals suffe ...
MAR 24, 2021
Cancer
What toxic chemicals are lurking in your couch?
MAR 24, 2021
What toxic chemicals are lurking in your couch?
New research published in the journal Environment International suggests a weekend trip to the nearest furniture st ...
MAR 31, 2021
Clinical & Molecular DX
A Non-Invasive Look at Fat Distribution in the Liver
MAR 31, 2021
A Non-Invasive Look at Fat Distribution in the Liver
The build-up of fat inside the liver is a worrying sign that points to the possibility of conditions such as nonalcoholi ...
MAR 30, 2021
Neuroscience
Prolonged Amygdala Activity Predicts Personal Wellbeing
MAR 30, 2021
Prolonged Amygdala Activity Predicts Personal Wellbeing
Researchers have found that activity in the amygdala (the emotional center of the brain) following exposure to negative ...
APR 09, 2021
Plants & Animals
Celebrating National Pet Day
APR 09, 2021
Celebrating National Pet Day
Sunday, April 11, is National Pet Day! From pandemic companions to viral videos, pets are a huge part of our lives. Even ...
APR 15, 2021
Clinical & Molecular DX
A Portable Ebola Detector, 1000x More Sensitive Than Lab-Based Tests
APR 15, 2021
A Portable Ebola Detector, 1000x More Sensitive Than Lab-Based Tests
Duke University scientists have created a highly sensitive Ebola virus portable diagnostic device, 1000 times more sensi ...
Loading Comments...